HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A Khamesipour Selected Research

Cutaneous Leishmaniasis

3/2015Effects of combined therapy with silymarin and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.
1/2014Interleukin 4 (IL-4) gene promoter polymorphisms in Rhombomys opimus, the main reservoir of zoonotic cutaneous leishmaniasis.
1/2012Interleukin-10 and Transforming Growth Factor-β in Early and Late Lesions of Patients with Leishmania major induced Cutaneous Leishmaniasis.
1/2012Interleukin-10 and Transforming Growth Factor-β in Early and Late Lesions of Patients with Leishmania major Induced Cutaneous Leishmaniasis.
1/2012IL-23 and IL-27 Levels in Macrophages Collected from Peripheral Blood of Patients with Healing Vs Non-Healing Form of Cutaneous Leishmaniasis.
7/2008CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis.
10/2007Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.
1/2005A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis.
11/2003Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.
10/2001Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


A Khamesipour Research Topics

Disease

10Cutaneous Leishmaniasis
03/2015 - 10/2001
9Leishmaniasis
09/2015 - 07/2008
5Infection
03/2015 - 08/2008
1Pemphigus (Pemphigus Vulgaris)
11/2007
1Skin Diseases
11/2007
1Bites and Stings (Sting)
11/2003
1Onychomycosis (Tinea Unguium)
06/2003

Drug/Important Bio-Agent (IBA)

4AntigensIBA
07/2008 - 10/2001
3CytokinesIBA
09/2015 - 01/2012
2meglumine antimoniateIBA
03/2015 - 10/2007
2Transforming Growth Factors (Transforming Growth Factor)IBA
01/2012 - 01/2012
2Interleukin-10 (Interleukin 10)IBA
01/2012 - 01/2012
2InterleukinsIBA
01/2012 - 01/2012
2Itraconazole (Sporanox)FDA LinkGeneric
01/2005 - 06/2003
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2015
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
09/2015
1Interleukin-17 (Interleukin 27)IBA
09/2015
1interleukin-22 (IL-22)IBA
09/2015
1SilymarinIBA
03/2015
1Interleukin-4 (Interleukin 4)IBA
01/2014
1Immunologic Factors (Immunomodulators)IBA
11/2013
1Interleukin-23 (Interleukin 23)IBA
01/2012
1PeroxiredoxinsIBA
08/2011
1tryparedoxin peroxidaseIBA
08/2011
1polylactic acid-polyglycolic acid copolymer (PLGA)IBA
12/2010
1Interferon-gamma (Interferon, gamma)IBA
08/2008
1Biological Markers (Surrogate Marker)IBA
07/2008
1AutoantibodiesIBA
11/2007
1Desmoglein 1IBA
11/2007
1Immunoglobulin G (IgG)IBA
11/2007
1AntibodiesIBA
11/2007
1BCG VaccineFDA Link
11/2003

Therapy/Procedure

1Aftercare (After-Treatment)
01/2012
1Nanospheres
12/2010